Research Study: RHAPSODY
Condition:
recurrent pericarditis
Study Sponsor: Kiniska Pharmaceuticals
Study Investigator: David Lin, MD
Study Contact: Christine Majeski
christine.majeski@allina.com
612-863-3546
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

This is a Phase 3, global, multi-center, double-blind, placebo-controlled, randomized withdrawal study with open-label extension, to assess the efficacy and safety of rilonacept treatment in subjects with recurrent pericarditis.
Eligibility Criteria:

  • Male or female aged 12 or older
  • Has a diagnosis of recurrent pericarditis
  • Must provide Informed Consent
  • Presents with at least the third episode of pericarditis during screening.
  • Has received Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination), if used, at stable dose levels (or at least not increased) for at least 3 days prior to first study drug administration
  • Female subjects must be postmenopausal, or incapable of pregnancy or permanently sterile, or if of childbearing potential must agree to use highly-effective method of contraception.
  • Must be up-to-date with all immunizations, in agreement with current local immunization guidelines for immunosuppressed subjects, before first study drug administration.
  • Is able to adequately maintain a daily subject diary according to protocol.
  • Agrees to refrain from making any new, major lifestyle changes that may affect pericarditis symptoms (e.g., changing exercise pattern) from the time that the informed consent form (ICF) is signed through the end of the double-blind randomized withdrawal period.

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!